Determining the Prevalence and Correlates of COVID-19 Booster Vaccine Hesitancy in the Singapore Population Following the Completion of the Primary Vaccination Series
Abstract
:1. Introduction
2. Materials and Methods
2.1. Setting and Participants
2.2. Measures
2.3. Statistical Analyses
3. Results
Multivariable Models of COVID-19 Booster Vaccine Hesitancy
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Moghadas, S.M.; Vilches, T.N.; Zhang, K.; Wells, C.R.; Shoukat, A.; Singer, B.H.; Meyers, L.A.; Neuzil, K.M.; Langley, J.M.; Fitzpatrick, M.C.; et al. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin. Infect. Dis. 2021, 73, 2257–2264. [Google Scholar] [CrossRef] [PubMed]
- Henry, D.A.; Jones, M.A.; Stehlik, P.; Glasziou, P.P. Effectiveness of COVID-19 vaccines: Findings from real world studies. Med. J. Aust. 2021, 215, 149. [Google Scholar] [CrossRef] [PubMed]
- Ministry of Health (MOH) Singapore. FAQs—Booster Doses. Available online: https://www.moh.gov.sg/covid-19/vaccination/faqs---booster-doses (accessed on 11 February 2022).
- Nordström, P.; Ballin, M.; Nordström, A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: A retrospective, total population cohort study in Sweden. Lancet 2022, 399, 814–823. [Google Scholar] [CrossRef]
- Ministry of Health (MOH) Singapore. Updates on Expanded Vaccination Programme, Facilitating our Vaccination Booster Programme. Available online: https://www.moh.gov.sg/news-highlights/details/updates-on-expanded-vaccination-programme-facilitating-our-vaccination-booster-programme (accessed on 16 May 2022).
- Ministry of Health (MOH) Singapore. Update on Local COVID-19 Situation (14 September). Available online: https://www.moh.gov.sg/news-highlights/details/update-on-local-covid-19-situation-(14-sep) (accessed on 17 May 2022).
- Abu Baker, J. Seniors Aged 60 and Above, Aged-Care Facility Residents to Get Invites for COVID-19 Booster Dose Vaccine: MOH. Available online: https://www.channelnewsasia.com/singapore/covid-19-vaccination-mrna-booster-dose-seniors-aged-care-residents-moh-2168826 (accessed on 11 February 2022).
- Abu Baker, J. COVID-19 Booster Jabs to Be Offered 5 Months after Second Dose for All Eligible Age Groups. Available online: https://www.channelnewsasia.com/singapore/covid-19-booster-dose-jabs-5-months-vaccination-moh-2327321 (accessed on 11 February 2022).
- Ministry of Health (MOH) Singapore. Start of Nuvaxovid COVID-19 Vaccination and Joint Testing Vaccination Centre Operations. Available online: https://www.moh.gov.sg/news-highlights/details/start-of-nuvaxovid-covid-19-vaccination-and-joint-testing-vaccination-centre-operations (accessed on 17 May 2022).
- Ganapathy, K. Only Fully Vaccinated Employees Can Return to Workplaces from January 1; Others Must Test Negative. Available online: https://www.channelnewsasia.com/singapore/only-fully-vaccinated-employees-can-return-workplace-unvaccinated-test-negative-2263807 (accessed on 12 June 2022).
- Griva, K.; Tan, K.Y.K.; Chan, F.H.F.; Periakaruppan, R.; Ong, B.W.L.; Soh, A.S.E.; Chen, M.I. Evaluating Rates and Determinants of COVID-19 Vaccine Hesitancy for Adults and Children in the Singapore Population: Strengthening Our Community’s Resilience against Threats from Emerging Infections (SOCRATEs) Cohort. Vaccines 2021, 9, 1415. [Google Scholar] [CrossRef]
- Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228. [Google Scholar] [CrossRef]
- Health Science Authority (HSA). Safety Updates on COVID-19 Vaccines. Available online: https://www.hsa.gov.sg/COVID19-vaccines-safety-updates (accessed on 17 May 2022).
- BioNTech to Expand Trial Programme for More Anti-Omicron COVID-19 Vaccine Options. Available online: https://www.channelnewsasia.com/world/biontech-expand-trial-programme-more-anti-omicron-covid-19-vaccine-options-2596326 (accessed on 17 May 2022).
- Hagger, M.S.; Hamilton, K. Predicting COVID-19 Booster Vaccine Intentions. Appl. Psychol. Health Well-Being 2022. online ahead of print. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention (CDC). Omicron Variant: What You Need to Know. Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html#:~:text=Omicron%20infection%20generally%20causes%20less,the%20infection%20with%20this%20variant. (accessed on 17 May 2022).
- Folcarelli, L.; Del Giudice, G.M.; Corea, F.; Angelillo, I.F. Intention to Receive the COVID-19 Vaccine Booster Dose in a University Community in Italy. Vaccines 2022, 10, 146. [Google Scholar] [CrossRef]
- Klugar, M.; Riad, A.; Mohanan, L.; Pokorná, A. COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study. Vaccines 2021, 9, 1437. [Google Scholar] [CrossRef]
- Rzymski, P.; Poniedziałek, B.; Fal, A. Willingness to receive the booster COVID-19 vaccine dose in Poland. Vaccines 2021, 9, 1286. [Google Scholar] [CrossRef]
- Al-Qerem, W.; Al Bawab, A.Q.; Hammad, A.; Ling, J.; Alasmari, F. Willingness of the Jordanian Population to Receive a COVID-19 Booster Dose: A Cross-Sectional Study. Vaccines 2022, 10, 410. [Google Scholar] [CrossRef]
- Lounis, M.; Bencherit, D.; Rais, M.A.; Riad, A. COVID-19 Vaccine Booster Hesitancy (VBH) and Its Drivers in Algeria: National Cross-Sectional Survey-Based Study. Vaccines 2022, 10, 621. [Google Scholar] [CrossRef]
- Qin, C.; Wang, R.; Tao, L.; Liu, M.; Liu, J. Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional Study. Vaccines 2022, 10, 89. [Google Scholar] [CrossRef]
- Jairoun, A.A.; Al-Hemyari, S.S.; El-Dahiyat, F.; Jairoun, M.; Shahwan, M.; Al Ani, M.; Habeb, M.; Babar, Z.-U.-D. Assessing public knowledge, attitudes and determinants of third COVID-19 vaccine booster dose acceptance: Current scenario and future perspectives. J. Pharm. Policy Pract. 2022, 15, 26. [Google Scholar] [CrossRef]
- Fernandes, N.; Costa, D.; Costa, D.; Keating, J.; Arantes, J. Predicting COVID-19 Vaccination Intention: The Determinants of Vaccine Hesitancy. Vaccines 2021, 9, 1161. [Google Scholar] [CrossRef]
- Parente, D.J.; Ojo, A.; Gurley, T.; LeMaster, J.W.; Meyer, M.; Wild, D.M.; Mustafa, R.A. Acceptance of COVID-19 Vaccination among Health System Personnel. J. Am. Board Fam. Med. 2021, 34, 498. [Google Scholar] [CrossRef]
- Lin, Y.; Hu, Z.; Zhao, Q.; Alias, H.; Danaee, M.; Wong, L.P. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl. Trop. Dis. 2020, 14, e0008961. [Google Scholar] [CrossRef]
- Chan, E. Benefits of mRNA COVID-19 Vaccines ‘Continue to Outweigh’ Risks: Singapore Expert Committee. Available online: https://www.channelnewsasia.com/singapore/mrna-covid-19-vaccine-outweigh-heart-risks-open-letter-committee-1937656 (accessed on 22 May 2022).
- Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 Subcommittee on Reports of Guillain-Barré Syndrome (GBS) following Adenovirus Vector COVID-19 Vaccines. Available online: https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs (accessed on 23 May 2022).
- COVID-19 mRNA Vaccines and Myocarditis: Benefits Outweigh the Risks, Says WHO Committee. Available online: https://news.un.org/en/story/2021/07/1095622 (accessed on 23 May 2022).
- Shiri, T.; Evans, M.; Talarico, C.A.; Morgan, A.R.; Mussad, M.; Buck, P.O.; McEwan, P.; Strain, W.D. The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. Vaccines 2022, 10, 140. [Google Scholar] [CrossRef]
- Sekizawa, Y.; Hashimoto, S.; Denda, K.; Ochi, S.; So, M. Association between COVID-19 Vaccine Hesitancy and Generalized Trust, Depression, Generalized Anxiety, and Fear of COVID-19. BMC Public Health 2022, 22, 126. [Google Scholar] [CrossRef]
- Chou, W.Y.S.; Budenz, A. Considering Emotion in COVID-19 Vaccine Communication: Addressing Vaccine Hesitancy and Fostering Vaccine Confidence. Health Commun. 2020, 35, 1718–1722. [Google Scholar] [CrossRef]
- Lim, V.W.; Lim, R.L.; Tan, Y.R.; Soh, A.S.E.; Tan, M.X.; Othman, N.B.; Dickens, S.B.; Thein, T.L.; Lwin, M.O.; Ong, R.T.H.; et al. Government trust, perceptions of COVID-19 and behaviour change: Cohort surveys, Singapore. Bull. World Health Organ. 2021, 99, 92–101. [Google Scholar] [CrossRef]
- Ang, Q. S’pore Reports 2396 New COVID-19 Cases and 8 Deaths, Weekly Infection Growth Rate at 0.87. Available online: https://str.sg/3fTF (accessed on 10 February 2022).
- Ministry of Health (MOH) Singapore. Update on Local COVID-19 Situation (11 November 2021). Available online: https://www.moh.gov.sg/news-highlights/details/update-on-local-covid-19-situation-(11-nov-2021) (accessed on 28 February 2022).
- Kroenke, K.; Spitzer, R.L.; Williams, J.B.W.; Monahan, P.O.; Löwe, B. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann. Intern. Med. 2007, 146, 317–325. [Google Scholar] [CrossRef]
- Kroenke, K.; Spitzer, R.L.; Williams, J.B.W. The patient health questionnaire-2: Validity of a two-item depression screener. Med. Care 2003, 41, 1284–1292. [Google Scholar] [CrossRef]
- Tsutsumi, S.; Maeda, N.; Tashiro, T.; Arima, S.; Mizuta, R.; Fukui, K.; Naito, K.; Komiya, M.; Urabe, Y. Willingness to Receive the COVID-19 Vaccination and the Psychological State of Japanese University Students: A Cross-Sectional Study. Int. J. Environ. Res. Public Health 2022, 19, 1654. [Google Scholar] [CrossRef]
- Bendau, A.; Plag, J.; Petzold, M.B.; Ströhle, A. COVID-19 vaccine hesitancy and related fears and anxiety. Int. Immunopharmacol. 2021, 97, 107724. [Google Scholar] [CrossRef]
- Bono, S.A.; Faria de Moura Villela, E.; Siau, C.S.; Chen, W.S.; Pengpid, S.; Hasan, M.T.; Sessou, P.; Ditekemena, J.D.; Amodan, B.O.; Hosseinipour, M.C.; et al. Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low- and Middle-Income Countries. Vaccines 2021, 9, 515. [Google Scholar] [CrossRef]
- Ng, K.Y.Y.; Zhou, S.; Tan, S.H.; Ishak, N.D.B.; Goh, Z.Z.S.; Chua, Z.Y.; Chia, J.M.X.; Chew, E.L.; Shwe, T.; Mok, J.K.Y.; et al. Understanding the psychological impact of COVID-19 pandemic on patients with cancer, their caregivers, and health care workers in Singapore. JCO Glob. Oncol. 2020, 6, 1494–1509. [Google Scholar] [CrossRef]
- Shmueli, L. Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model. BMC Public Health 2021, 21, 804. [Google Scholar] [CrossRef]
- Wong, M.C.S.; Wong, E.L.Y.; Huang, J.; Cheung, A.W.L.; Law, K.; Chong, M.K.C.; Ng, R.W.Y.; Lai, C.K.C.; Boon, S.S.; Lau, J.T.F.; et al. Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong. Vaccine 2021, 39, 1148–1156. [Google Scholar] [CrossRef]
- Chen, H.; Li, X.; Gao, J.; Liu, X.; Mao, Y.; Wang, R.; Zheng, P.; Xiao, Q.; Jia, Y.; Fu, H.; et al. Health Belief Model Perspective on the Control of COVID-19 Vaccine Hesitancy and the Promotion of Vaccination in China: Web-Based Cross-Sectional Study. J. Med. Internet Res. 2021, 23, e29329. [Google Scholar] [CrossRef]
- Yahaghi, R.; Ahmadizade, S.; Fotuhi, R.; Taherkhani, E.; Ranjbaran, M.; Buchali, Z.; Jafari, R.; Zamani, N.; Shahbazkhania, A.; Simiari, H.; et al. Fear of COVID-19 and perceived COVID-19 infectability supplement theory of planned behavior to explain iranians’ intention to get COVID-19 vaccinated. Vaccines 2021, 9, 684. [Google Scholar] [CrossRef]
- Xiao, X.; Wong, R.M. Vaccine hesitancy and perceived behavioral control: A meta-analysis. Vaccine 2020, 38, 5131–5138. [Google Scholar] [CrossRef] [PubMed]
- Lin, C.-Y.; Imani, V.; Majd, N.R.; Ghasemi, Z.; Griffiths, M.D.; Hamilton, K.; Hagger, M.S.; Pakpour, A.H. Using an integrated social cognition model to predict COVID-19 preventive behaviours. Br. J. Health Psychol. 2020, 25, 981–1005. [Google Scholar] [CrossRef] [PubMed]
- Glanz, K.; Bishop, D.B. The Role of Behavioral Science Theory in Development and Implementation of Public Health Interventions. Annu. Rev. Public Health 2010, 31, 399–418. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Raude, J.; Lecrique, J.-M.; Lasbeur, L.; Leon, C.; Guignard, R.; du Roscoät, E.; Arwidson, P. Determinants of Preventive Behaviors in Response to the COVID-19 Pandemic in France: Comparing the Sociocultural, Psychosocial, and Social Cognitive Explanations. Front. Psychol. 2020, 11, 584500. [Google Scholar] [CrossRef]
- Eberhardt, J.; Ling, J. Predicting COVID-19 vaccination intention using protection motivation theory and conspiracy beliefs. Vaccine 2021, 39, 6269–6275. [Google Scholar] [CrossRef]
- Huang, P.-C.; Hung, C.-H.; Kuo, Y.-J.; Chen, Y.-P.; Ahorsu, D.K.; Yen, C.-F.; Lin, C.-Y.; Griffiths, M.D.; Pakpour, A.H. Expanding Protection Motivation Theory to Explain Willingness of COVID-19 Vaccination Uptake among Taiwanese University Students. Vaccines 2021, 9, 1046. [Google Scholar] [CrossRef]
- Janz, N.K.; Becker, M.H. The Health Belief Model: A Decade Later. Health Educ. Behav. 1984, 11, 1–47. [Google Scholar] [CrossRef] [Green Version]
- Shahnazi, H.; Ahmadi-Livani, M.; Pahlavanzadeh, B.; Rajabi, A.; Hamrah, M.S.; Charkazi, A. Assessing preventive health behaviors from COVID-19: A cross sectional study with health belief model in Golestan Province, Northern of Iran. Infect. Dis. Poverty 2020, 9, 91–99. [Google Scholar] [CrossRef]
- Horne, R.; Chapman, S.C.E.; Parham, R.; Freemantle, N.; Forbes, A.; Cooper, V. Understanding Patients’ Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: A Meta-Analytic Review of the Necessity-Concerns Framework. PLoS ONE 2013, 8, e80633. [Google Scholar] [CrossRef]
- Clifford, S.; Barber, N.; Horne, R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: Application of the Necessity–Concerns Framework. J. Psychosom. Res. 2008, 64, 41–46. [Google Scholar] [CrossRef]
- Elangovan, N. COVID-19 Vaccine Booster Shots for Healthcare and Frontline Workers, Residents of Care Facilities, Those Aged 30 and Above. Available online: https://www.todayonline.com/singapore/covid-19-vaccine-booster-shots-healthcare-and-frontline-workers-residents-care-facilities (accessed on 17 May 2022).
- Tang, S.K. COVID-19 Booster Shot Needed to Maintain Fully Vaccinated Status from 14 February: MOH. Available online: https://www.channelnewsasia.com/singapore/covid-19-booster-shots-needed-maintain-fully-vaccinated-status-feb-14-moh-2416586 (accessed on 8 June 2022).
- Ministry of Health (MOH) Singapore. Vaccination Statistics. Available online: https://www.moh.gov.sg/covid-19/vaccination/statistics (accessed on 23 June 2022).
- Yoshida, M.; Kobashi, Y.; Kawamura, T.; Shimazu, Y.; Nishikawa, Y.; Omata, F.; Zhao, T.; Yamamoto, C.; Kaneko, Y.; Nakayama, A.; et al. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey. Vaccines 2022, 10, 515. [Google Scholar] [CrossRef]
- Okubo, R.; Yoshioka, T.; Ohfuji, S.; Matsuo, T.; Tabuchi, T. COVID-19 vaccine hesitancy and its associated factors in Japan. Vaccines 2021, 9, 662. [Google Scholar] [CrossRef]
- Begum, S.; Yeo, S.H. GPs, Community Groups Working to Persuade Seniors in S’pore to Get Vaccinated. Available online: https://www.straitstimes.com/singapore/community/gps-community-groups-working-to-persuade-seniors-to-get-vaccinated (accessed on 18 May 2022).
- Olagoke, A.A.; Olagoke, O.O.; Hughes, A.M. Intention to Vaccinate Against the Novel 2019 Coronavirus Disease: The Role of Health Locus of Control and Religiosity. J. Relig. Health 2021, 60, 65–80. [Google Scholar] [CrossRef]
- Wang, J.; Zhang, Y.; Long, S.; Fu, X.; Zhang, X.; Zhao, S.; Xiu, S.; Wang, X.; Lu, B.; Jin, H. Non-epi vaccine hesitancy among chinese adults: A cross-sectional study. Vaccines 2021, 9, 772. [Google Scholar] [CrossRef]
- Yu, B.Y.-M.; Lam, J.C.-S.; Lam, S.C.; Li, Y.; Chen, S.; Lam, M.Y.; Yeung, W.-F. COVID-19 vaccine hesitancy and resistance in an urban Chinese population of Hong Kong: A cross-sectional study. Hum. Vaccines Immunother. 2022, 2072144, online ahead of print. [Google Scholar] [CrossRef]
- Bai, W.; Cai, H.; Liu, S.; Liu, H.; Qi, H.; Chen, X.; Liu, R.; Cheung, T.; Su, Z.; Ng, C.H.; et al. Attitudes toward COVID-19 vaccines in Chinese college students. Int. J. Biol. Sci. 2021, 17, 1469–1475. [Google Scholar] [CrossRef]
- Petzold, M.B.; Bendau, A.; Plag, J.; Pyrkosch, L.; Maricic, L.M.; Rogoll, J.; Betzler, F.; Große, J.; Ströhle, A. Development of the COVID-19-Anxiety Questionnaire and first psychometric testing. BJPsych Open 2020, 6, e91. [Google Scholar] [CrossRef]
- Betsch, C.; Ulshöfer, C.; Renkewitz, F.; Betsch, T. The influence of narrative v. statistical information on perceiving vaccination risks. Med. Decis. Mak. 2011, 31, 742–753. [Google Scholar] [CrossRef]
- Nazlı, Ş.B.; Yığman, F.; Sevindik, M.; Deniz Özturan, D. Psychological factors affecting COVID-19 vaccine hesitancy. Ir. J. Med. Sci. 2022, 191, 71–80. [Google Scholar] [CrossRef]
- Almaghaslah, D.; Alsayari, A.; Kandasamy, G.; Vasudevan, R. COVID-19 Vaccine Hesitancy among Young Adults in Saudi Arabia: A Cross-Sectional Web-Based Study. Vaccines 2021, 9, 330. [Google Scholar] [CrossRef]
- Guillon, M.; Kergall, P. Factors associated with COVID-19 vaccination intentions and attitudes in France. Public Health 2021, 198, 200–207. [Google Scholar] [CrossRef]
- Riad, A.; Huang, Y.; Abdulqader, H.; Morgado, M.; Domnori, S.; Koščík, M.; Mendes, J.J.; Klugar, M.; Kateeb, E.; Iads, S. Universal predictors of dental students’ attitudes towards COVID-19 vaccination: Machine learning-based approach. Vaccines 2021, 9, 1158. [Google Scholar] [CrossRef]
- Soares, P.; Rocha, J.V.; Moniz, M.; Gama, A.; Laires, P.A.; Pedro, A.R.; Dias, S.; Leite, A.; Nunes, C. Factors Associated with COVID-19 Vaccine Hesitancy. Vaccines 2021, 9, 300. [Google Scholar] [CrossRef]
- Kricorian, K.; Civen, R.; Equils, O. COVID-19 vaccine hesitancy: Misinformation and perceptions of vaccine safety. Hum. Vaccines Immunother. 2022, 18, 1950504. [Google Scholar] [CrossRef]
- Le, C.N.; Nguyen, U.T.T.; Do, D.T.H. Predictors of COVID-19 vaccine acceptability among health professions students in Vietnam. BMC Public Health 2022, 22, 854. [Google Scholar] [CrossRef]
- Malik, A.A.; McFadden, S.M.; Elharake, J.; Omer, S.B. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine 2020, 26, 100495. [Google Scholar] [CrossRef]
- Dror, A.A.; Eisenbach, N.; Taiber, S.; Morozov, N.G.; Mizrachi, M.; Zigron, A.; Srouji, S.; Sela, E. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur. J. Epidemiol. 2020, 35, 775–779. [Google Scholar] [CrossRef]
- Lucia, V.C.; Kelekar, A.; Afonso, N.M. COVID-19 vaccine hesitancy among medical students. J. Public Health 2020, 43, 445–449. [Google Scholar] [CrossRef]
- Liu, T.; He, Z.; Huang, J.; Yan, N.; Chen, Q.; Huang, F.; Zhang, Y.; Akinwunmi, O.M.; Akinwunmi, B.O.; Zhang, C.J.P.; et al. A Comparison of Vaccine Hesitancy of COVID-19 Vaccination in China and the United States. Vaccines 2021, 9, 649. [Google Scholar] [CrossRef]
- Lim, V. Children Aged 12 to 17 Must Get COVID-19 Booster within 270 Days of 2nd Dose to Maintain Fully Vaccinated Status. Available online: https://www.channelnewsasia.com/singapore/mtf-children-covid-19-booster-270-days-second-dose-fully-vaccinated-status-2450426 (accessed on 8 June 2022).
- Mercer, P. New Zealand to Scrap Some Controversial COVID-19 Vaccine Mandates. Available online: https://www.voanews.com/a/new-zealand-to-scrap-some-controversial-covid-19-vaccine-mandates/6497397.html (accessed on 13 June 2022).
- COVID in Europe: France to Scrap Face Masks and Vaccine Passes on 14 March. Available online: https://www.euronews.com/2022/03/03/covid-in-europe-france-to-scrap-face-masks-and-vaccine-passes-on-14-march (accessed on 13 June 2022).
- Harris, S. Several Provinces Are Dropping Vaccine Passports, but Some Businesses Aren’t on Board. Available online: https://www.cbc.ca/news/business/provincial-vaccine-mandate-business-1.6354502 (accessed on 13 June 2022).
- Singstats. Population Trends; Department of Statistics Singapore: Singapore, 2021; pp. 1–50.
- Wang, Y.; Hunt, K.; Nazareth, I.; Freemantle, N.; Petersen, I. Do men consult less than women? An analysis of routinely collected UK general practice data. BMJ Open 2013, 3, e003320. [Google Scholar] [CrossRef] [Green Version]
- Arroll, B.; Goodyear-Smith, F.; Crengle, S.; Gunn, J.; Kerse, N.; Fishman, T.; Falloon, K.; Hatcher, S. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann. Fam. Med. 2010, 8, 348–353. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Silva, W.A.D.; de Sampaio Brito, T.R.; Pereira, C.R. COVID-19 anxiety scale (CAS): Development and psychometric properties. Curr. Psychol. 2020, 1–10, online ahead of print. [Google Scholar] [CrossRef] [PubMed]
Variables | Total N (%) | Non-Hesitant N (%) | Hesitant N (%) | p-Value | Univariate OR 1 | 95% CI 2 |
---|---|---|---|---|---|---|
Total | 1005 (100.0) | 698 (69.5) | 307 (30.5) | |||
Gender | ||||||
Male | 381 (37.9) | 273 (71.7) | 108 (28.3) | 0.237 | 0.845 | 0.639–1.117 |
Female | 624 (62.1) | 425 (68.1) | 199 (31.9) | Ref | ||
Race | ||||||
Chinese | 898 (89.4) | 619 (68.9) | 279 (31.1) | Ref | ||
Malay | 28 (2.8) | 22 (78.6) | 6 (21.4) | 0.281 | 0.605 | 0.243–1.509 |
Indian | 53 (5.3) | 40 (75.5) | 13 (24.5) | 0.318 | 0.721 | 0.380–1.370 |
Others | 26 (2.6) | 17 (65.4) | 9 (34.6) | 0.701 | 1.175 | 0.517–2.667 |
Mean Age (SD) | 42.58 (13.5) 3 | 42.3 (13.4) 3 | 43.3 (13.7) 3 | |||
Age | ||||||
18–29 years | 210 (20.9) | 145 (69.0) | 65 (31.0) | 0.076 | 0.648 | 0.401–1.046 |
30–44 years | 350 (34.8) | 254 (72.6) | 96 (27.4) | 0.008 | 0.546 | 0.349–0.853 |
45–59 years | 335 (33.3) | 234 (69.9) | 101 (30.1) | 0.038 | 0.623 | 0.399–0.974 |
60 years and above 4 | 110 (10.9) | 65 (59.1) | 45 (40.9) | Ref | ||
Highest Education | ||||||
No Formal Education/ Primary Education | 21 (2.1) | 18 (85.7) | 3 (14.3) | 0.094 | 0.349 | 0.102–1.199 |
Secondary/ Postsecondary Education | 387 (38.5) | 276 (71.3) | 111 (28.7) | 0.227 | 0.842 | 0.637–1.113 |
Tertiary Education | 597 (59.4) | 404 (67.7) | 193 (32.3) | Ref | ||
Housing Type | ||||||
1–3 room HDB 5 | 133 (13.2) | 90 (67.7) | 43 (32.3) | 0.560 | 1.127 | 0.754–1.684 |
4–5 room HDB/Executive Apartment/DBSS/HUDC 6 | 628 (62.5) | 441 (70.2) | 187 (29.8) | Ref | ||
Condominium/Landed Property | 244 (24.3) | 167 (68.4) | 77 (31.6) | 0.608 | 1.087 | 0.790–1.497 |
Monthly Household Income | ||||||
SGD 4999 and below | 307 (30.5) | 209 (68.1) | 98 (31.9) | Ref | ||
SGD 5000–8999 | 283 (28.2) | 193 (68.2) | 90 (31.8) | 0.975 | 0.995 | 0.703–1.407 |
SGD 9000–12,999 | 230 (22.9) | 160 (69.6) | 70 (30.4) | 0.713 | 0.933 | 0.645–1.350 |
SGD 13,000 and above | 185 (18.4) | 136 (73.5) | 49 (26.5) | 0.203 | 0.768 | 0.512–1.152 |
Occupation Status | ||||||
Employed | 603 (60.0) | 438 (72.6) | 165 (27.4) | Ref | ||
Student | 101 (10.0) | 72 (71.3) | 29 (28.7) | 0.779 | 1.069 | 0.670–1.705 |
Self-employed | 133 (13.2) | 80 (60.2) | 53 (39.8) | 0.005 | 1.759 | 1.190–2.599 |
Not employed or student | 168 (16.7) | 108 (64.30 | 60 (35.7) | 0.036 | 1.475 | 1.026–2.120 |
Daily Regular Contact(s) | ||||||
Less than 10 people | 500 (49.8) | 332 (66.4) | 168 (33.6) | Ref | ||
10–19 people | 223 (22.2) | 153 (68.6) | 70 (31.4) | 0.559 | 0.904 | 0.645–1.268 |
20–49 people | 187 (18.6) | 137 (73.3) | 50 (26.7) | 0.086 | 0.721 | 0.497–1.048 |
50 or more people | 95 (9.5) | 76 (80.0) | 19 (20.0) | 0.010 | 0.494 | 0.289–0.844 |
GAD-2 | ||||||
Below cut point (Total score < 3) | 897 (89.3) | 629 (90.1) | 268 (87.3) | Ref | ||
At or above cut point (Total score ≥ 3) | 108 (10.7) | 69 (9.9) | 39 (12.7) | 0.269 | 1.167 | 0.887–1.535 |
PHQ-2 | ||||||
Below cut point (total score < 3) | 872 (86.8) | 611 (87.5) | 261 (85.0) | Ref | ||
At or above cut point (Total score ≥ 3) | 133 (13.2) | 87 (12.5) | 46 (15.0) | 0.595 | 1.079 | 0.815–1.429 |
Living with people in poor health | ||||||
No | 936 (93.1) | 655 (70.0) | 281 (30.0) | Ref | ||
Yes | 69 (6.9) | 43 (62.3) | 26 (37.7) | 0.184 | 1.409 | 0.849–2.339 |
Living with unvaccinated people | ||||||
No | 887 (88.3) | 618 (69.7) | 269 (30.3) | Ref | ||
Yes | 118 (11.7) | 80 (67.8) | 38 (32.2) | 0.678 | 1.091 | 0.723–1.647 |
Living with people vulnerable to COVID-19 (e.g., elderly) | ||||||
No | 924 (91.9) | 645 (69.8) | 279 (30.2) | Ref | ||
Yes | 81 (8.1) | 53 (65.4) | 28 (34.6) | 0.413 | 1.221 | 0.757–1.972 |
Living with children between 0 to 11 years old | ||||||
No | 977 (97.2) | 682 (69.8) | 295 (30.2) | Ref | ||
Yes | 28 (2.8) | 16 (57.1) | 12 (42.9) | 0.156 | 1.734 | 0.810–3.711 |
Negative Benefits/Concerns Differential Score | 394 (39.2) | 168 (24.1) | 226 (73.6) | |||
Positive Benefits/Concerns Differential Score | 611 (60.8) | 530 (75.9) | 81 (26.4) |
Variables | Total M (SD) | Non-Hesitant M (SD) | Hesitant M (SD) | p-Value | Univariate OR 1 | 95% CI 2 |
---|---|---|---|---|---|---|
Fear | 1.95 (0.94) | 1.94 (0.91) | 1.99 (1.00) | 0.394 | 1.060 | 0.928–1.210 |
Anxiety | 1.97 (0.97) | 1.94 (0.94) | 2.04 (1.02) | 0.147 | 1.103 | 0.966–1.259 |
Anger | 1.79 (1.00) | 1.74 (0.94) | 1.91 (1.13) | 0.020 | 1.168 | 1.025–1.332 |
Disgust | 1.66 (0.98) | 1.61 (0.92) | 1.79 (1.10) | 0.008 | 1.191 | 1.046–1.356 |
Helplessness | 1.96 (1.12) | 1.91 (1.09) | 2.08 (1.20) | 0.026 | 1.161 | 1.018–1.323 |
Perceived Risk of COVID-19 | 3.65 (0.70) | 3.67 (0.68) | 3.59 (0.75) | 0.116 | 0.898 | 0.786–1.027 |
Perceived Benefits | 3.52 (0.78) | 3.81 (0.61) | 2.86 (0.71) | <0.001 | 0.159 | 0.124–0.205 |
Necessity for booster vaccine | 3.35 (0.91) | 3.63 (0.83) | 2.72 (0.76) | <0.001 | 0.283 | 0.234–0.343 |
Perceived Concerns | 3.19 (0.84) | 2.99 (0.81) | 3.64 (0.72) | <0.001 | 2.617 | 2.194–3.122 |
Benefits/Concerns Differential | 0.34 (1.41) | 0.83 (1.19) | −0.78 (1.22) | <0.001 | 0.187 | 0.147–0.237 |
Variables | OR 1 | p-Value | 95% CI 2 | ||
---|---|---|---|---|---|
Lower | Upper | ||||
Sociodemographic Variables | |||||
Gender | Female | Ref | |||
Male | 0.850 | 0.405 | 0.580 | 1.246 | |
Race | Chinese | Ref | |||
Malay | 0.808 | 0.707 | 0.267 | 2.452 | |
Indian | 0.578 | 0.208 | 0.246 | 1.356 | |
Others | 1.571 | 0.427 | 0.515 | 4.791 | |
Age | 18 to 29 years | 1.110 | 0.797 | 0.501 | 2.460 |
30 to 44 years | 0.521 | 0.067 | 0.260 | 1.047 | |
45 to 59 years | 0.738 | 0.359 | 0.385 | 1.413 | |
60 years and above 3 | Ref | ||||
Highest Education | No Formal Education/ Primary Education | 0.109 | 0.009 | 0.021 | 0.577 |
Secondary/Postsecondary Education | 0.540 | 0.005 | 0.352 | 0.827 | |
Tertiary Education | Ref | ||||
Housing Type | 1–3 room HDB | 1.180 | 0.565 | 0.671 | 2.075 |
4–5 room HDB/Executive Apartment/DBSS/HUDC | Ref | ||||
Condominium/Landed Property | 0.924 | 0.725 | 0.595 | 1.435 | |
Monthly Household Income | SGD 4999 and below | Ref | |||
SGD 5000–8999 | 1.047 | 0.852 | 0.644 | 1.704 | |
SGD 9000–12,999 | 1.241 | 0.411 | 0.742 | 2.077 | |
SGD 13,000 and above | 0.847 | 0.568 | 0.479 | 1.498 | |
Occupation Status | Employed | Ref | |||
Student | 1.666 | 0.215 | 0.743 | 3.733 | |
Self-Employed | 1.618 | 0.077 | 0.949 | 2.760 | |
Not employed or student | 1.013 | 0.963 | 0.574 | 1.788 | |
Daily Regular Contact(s) | Less than 10 people | Ref | |||
10–19 people | 0.837 | 0.443 | 0.532 | 1.318 | |
20–49 people | 0.794 | 0.383 | 0.472 | 1.334 | |
50 or more people | 0.681 | 0.269 | 0.344 | 1.346 | |
Living with people in poor health | No | Ref | |||
Yes | 1.155 | 0.682 | 0.580 | 2.299 | |
Living with unvaccinated people | No | Ref | |||
Yes | 1.335 | 0.317 | 0.758 | 2.349 | |
Living with people vulnerable to COVID-19 (e.g., elderly) | No | Ref | |||
Yes | 1.100 | 0.779 | 0.564 | 2.147 | |
Living with children between 0 to 11 years old | No | Ref | |||
Yes | 1.877 | 0.235 | 0.664 | 5.304 | |
Psychological Variables (Stepwise Forward Method, in order of entry) | |||||
Perceived Benefits | 0.257 | <0.001 | 0.193 | 0.342 | |
Necessity for booster vaccine | 0.537 | <0.001 | 0.421 | 0.684 | |
Perceived Concerns | 1.698 | <0.001 | 1.314 | 2.195 | |
Perceived Risk of COVID-19 | 0.790 | 0.031 | 0.638 | 0.978 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tan, K.Y.K.; Soh, A.S.E.; Ong, B.W.L.; Chen, M.I.; Griva, K. Determining the Prevalence and Correlates of COVID-19 Booster Vaccine Hesitancy in the Singapore Population Following the Completion of the Primary Vaccination Series. Vaccines 2022, 10, 1088. https://doi.org/10.3390/vaccines10071088
Tan KYK, Soh ASE, Ong BWL, Chen MI, Griva K. Determining the Prevalence and Correlates of COVID-19 Booster Vaccine Hesitancy in the Singapore Population Following the Completion of the Primary Vaccination Series. Vaccines. 2022; 10(7):1088. https://doi.org/10.3390/vaccines10071088
Chicago/Turabian StyleTan, Kevin Y. K., Alexius S. E. Soh, Brenda W. L. Ong, Mark IC. Chen, and Konstadina Griva. 2022. "Determining the Prevalence and Correlates of COVID-19 Booster Vaccine Hesitancy in the Singapore Population Following the Completion of the Primary Vaccination Series" Vaccines 10, no. 7: 1088. https://doi.org/10.3390/vaccines10071088
APA StyleTan, K. Y. K., Soh, A. S. E., Ong, B. W. L., Chen, M. I., & Griva, K. (2022). Determining the Prevalence and Correlates of COVID-19 Booster Vaccine Hesitancy in the Singapore Population Following the Completion of the Primary Vaccination Series. Vaccines, 10(7), 1088. https://doi.org/10.3390/vaccines10071088